AU621592B2 - Treatment of abnormal bone conditions using interleukin-6 - Google Patents

Treatment of abnormal bone conditions using interleukin-6 Download PDF

Info

Publication number
AU621592B2
AU621592B2 AU30942/89A AU3094289A AU621592B2 AU 621592 B2 AU621592 B2 AU 621592B2 AU 30942/89 A AU30942/89 A AU 30942/89A AU 3094289 A AU3094289 A AU 3094289A AU 621592 B2 AU621592 B2 AU 621592B2
Authority
AU
Australia
Prior art keywords
ala
bone
molecule
interleukin
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30942/89A
Other languages
English (en)
Other versions
AU3094289A (en
Inventor
Jean Honore M. Feyen
Ulrich Trechsel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888805231A external-priority patent/GB8805231D0/en
Priority claimed from GB888810899A external-priority patent/GB8810899D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU3094289A publication Critical patent/AU3094289A/en
Application granted granted Critical
Publication of AU621592B2 publication Critical patent/AU621592B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU30942/89A 1988-03-04 1989-03-02 Treatment of abnormal bone conditions using interleukin-6 Ceased AU621592B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8805231 1988-03-04
GB888805231A GB8805231D0 (en) 1988-03-04 1988-03-04 Improvements in/relating to organic compounds
GB888810899A GB8810899D0 (en) 1988-05-09 1988-05-09 Improvements in/relating to organic compounds
GB8810899 1988-05-09

Publications (2)

Publication Number Publication Date
AU3094289A AU3094289A (en) 1989-09-07
AU621592B2 true AU621592B2 (en) 1992-03-19

Family

ID=26293587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30942/89A Ceased AU621592B2 (en) 1988-03-04 1989-03-02 Treatment of abnormal bone conditions using interleukin-6

Country Status (17)

Country Link
EP (1) EP0331640A3 (enExample)
JP (1) JPH01308234A (enExample)
KR (1) KR890014124A (enExample)
AU (1) AU621592B2 (enExample)
BE (1) BE1003662A4 (enExample)
CA (1) CA1332223C (enExample)
CH (1) CH680070A5 (enExample)
DE (1) DE3906923A1 (enExample)
DK (1) DK102389A (enExample)
FR (1) FR2628323B1 (enExample)
GB (1) GB2216412B (enExample)
HU (1) HUT52962A (enExample)
IT (1) IT1230496B (enExample)
NL (1) NL8900524A (enExample)
PH (1) PH26238A (enExample)
PT (1) PT89893A (enExample)
SE (1) SE8900722L (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03197433A (ja) * 1989-12-26 1991-08-28 Otsuka Pharmaceut Co Ltd Ｉｌ―６産生誘導剤
IT1263022B (it) * 1992-11-06 1996-07-23 Angeletti P Ist Richerche Bio Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica.
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
GB9610281D0 (en) * 1996-05-16 1996-07-24 Ralston Stuart H Diagnostic method and apparatus
JP2001158736A (ja) * 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd 骨関節疾患の予防及び改善剤
FI112031B (fi) * 2002-02-25 2003-10-31 Valio Oy Biologisesti aktiivisen tuotteen uusi käyttö
EP1596869B1 (en) 2003-01-21 2014-06-04 New Form Pharmaceuticals Inc. Novel cocrystallization
ATE464908T1 (de) * 2004-02-11 2010-05-15 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
GB0912159D0 (en) * 2009-07-14 2009-08-26 Imp Innovations Ltd Methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7696287A (en) * 1986-07-08 1988-01-29 Genetics Institute, Llc Production and use of il-6
AU4310889A (en) * 1988-09-14 1990-04-02 Scripps Clinic And Research Foundation Methods for increasing c1 inhibitor concentrations using interferon and/or interleukin-6

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750106T3 (de) * 1986-08-06 1999-04-22 Ajinomoto Co., Inc., Tokio/Tokyo Rekombinanter B-Zell-Differenzierungsfaktor.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7696287A (en) * 1986-07-08 1988-01-29 Genetics Institute, Llc Production and use of il-6
AU4310889A (en) * 1988-09-14 1990-04-02 Scripps Clinic And Research Foundation Methods for increasing c1 inhibitor concentrations using interferon and/or interleukin-6

Also Published As

Publication number Publication date
DK102389A (da) 1989-09-05
NL8900524A (nl) 1989-10-02
HUT52962A (en) 1990-09-28
CA1332223C (en) 1994-10-04
JPH01308234A (ja) 1989-12-12
AU3094289A (en) 1989-09-07
SE8900722D0 (sv) 1989-03-02
IT8947695A0 (it) 1989-03-01
FR2628323B1 (fr) 1994-09-09
FR2628323A1 (fr) 1989-09-15
KR890014124A (ko) 1989-10-21
IT1230496B (it) 1991-10-24
GB2216412B (en) 1991-10-02
EP0331640A2 (en) 1989-09-06
GB2216412A (en) 1989-10-11
PT89893A (pt) 1989-11-10
PH26238A (en) 1992-04-01
SE8900722L (sv) 1989-09-05
BE1003662A4 (fr) 1992-05-19
CH680070A5 (enExample) 1992-06-15
DE3906923A1 (de) 1989-09-14
EP0331640A3 (en) 1991-03-13
GB8904646D0 (en) 1989-04-12
DK102389D0 (da) 1989-03-02

Similar Documents

Publication Publication Date Title
AU666866B2 (en) Hybrid cytokines
US6066317A (en) Method of using IL-11 for treating deficiencies in hematopoietic progenitor or stem cells
Slootweg et al. Osteoclast formation together with interleukin-6 production in mouse long bones is increased by insulin-like growth factor-I
AU621592B2 (en) Treatment of abnormal bone conditions using interleukin-6
CA2078547A1 (en) Method of predisposing mammals to accelerated tissue repair
Evely et al. Structural requirements for the action of parathyroid hormone‐related protein (PTHrP) on bone resorption by isolated osteoclasts
WO1997000317A1 (en) Osteoclast growth regulatory factor
IE861422L (en) Use of ifn - x for inhibiting bone degradation
US6787518B1 (en) Therapeutics of osteoarthritis and inflammatory joint disease
Hakeda et al. Existence of parathyroid hormone binding sites on murine hemopoietic blast cells
Gala et al. Evidence for the release of a prolactin-like substance by mouse lymphocytes and macrophages
US6171824B1 (en) Hybrid cytokines
Fenton et al. Carboxyl‐terminal parathyroid hormone‐related protein inhibits bone resorption by isolated chicken osteoclasts
Kagechika et al. Inhibition of IL-1-induced IL-6 production by synthetic retinoids
EP0686397A2 (en) Use of chondroitin sulphate proteoglycans for protection of neurons
Jimi et al. Basic fibroblast growth factor inhibits osteoclast‐like cell formation
STEWART et al. Synthetic parathyroid hormone-like protein-(1–74): Biochemical and physiological characterization
Lorenzo Cytokines and bone metabolism: resorption and formation
CA2094835A1 (en) Stimulator for bone formation
UDA et al. Stable human calcitonin analogues with high potency on bone together with reduced anorectic and renal actions
US6815417B1 (en) Method for treating obesity and for inhibiting adipocyte activity
CA2152023A1 (en) Agents for treating metabolic bone diseases
AU644389C (en) A mammalian cytokine, IL-11
JP4786843B2 (ja) インターロイキン−６から誘導されるレトロ−インベルソペプチド
Zhang et al. Effects of calcitonin gene-related peptide on bone resorption mediated by interleukin-1